At the same time, it has also asked Indian Council of Medical Research (ICMR) to prepare an action plan on antimicrobial resistance on a "priority" basis and work on standardisation of protocol to administer antibiotics.
It has also asked ICMR to take up a national level sensitisation process for the medical community.
"The committee recommends that ICMR should focus its research on multi-drug resistant TB strains with a view to discovering potent drug combinations combating MDRTB," the committee on Demands for Grants 2017-18 of Department of Health Research said.
"Though the government has rolled out the administration of Bedaquiline, the first TB drug approval by the USFDA in over 40 years in six public health hospitals in the country to specifically treat MDRTB, a lot remains to be done to improve MDRTB treatment outcomes," said the committee chaired by Ram Gopal Yadav.
The World Health Organisation had recently said that MDRTB burden largely falls on three nations - China, India, and Russia - which together account for nearly half of all global cases.
"The committee believes that a dedicated action plan on antimicrobial resistance including antibiotic resistance needs to be prepared by ICMR on a priority basis.
"The committee strongly recommends for standardisation of protocol for the administration of antibiotics and expects that a process of sensitising the medical community about the perils of antibiotic resistance should be taken up on a national scale by involving medical and industry associations, medical academia, media and other groups," it said.
The committee also said "aggressive" awareness generation programmes regarding use of antibiotics without a prescription must be taken up to educate people in this regard.
The government has termed AMR as a "big" challenge and had recently said it is moving towards a mechanism of auditing prescriptions to monitor what drug is being prescribed and detailed guidelines.
The government has also announced the launch of a campaign next week involving four ministries to strategise to contain AMR.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
